Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
Inv. presentation
Annexon, Inc. (ANNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/07/2023 8-K Quarterly results
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 30,251 $ 29,106 $ 62,596 $ 56,104 General and administrative 7,440 8,303 16,337 16,731 Total operating expenses 37,691 37,409 78,933 72,835 Loss from operations Interest and other income, net 2,503 272 5,069 325 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share, basic and diluted 75,230,003 38,584,400 74,546,995 38,573,950 _______________________ Includes the following stock-based compensation expense: Research and development $ 2,307 $ 2,117 $ 4,558 $ 4,076 General and administrative $ 2,353 $ 2,403 $ 4,709 $ 4,696 ANNEXON, INC. Cond..."
07/31/2023 8-K Quarterly results
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function"
05/08/2023 8-K Quarterly results
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 32,345 $ 26,998 General and administrative 8,897 8,428 Total operating expenses 41,242 35,426 Loss from operations Interest and other income, net 2,566 53 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares used in computing net loss per share, basic and diluted 73,855,642 38,563,384 _______________________ Includes the following stock-based compensation expense: Research and development $ 2,251 $ 1,959 General and administrative $ 2,356 $ 2,293 ANNEXON, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 144,120 $ 140,020 Short-term investme..."
03/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ANNEXON, INC. Condensed Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 28,535 $ 27,217 $ 112,501 $ 100,066 General and administrative 8,160 10,241 33,098 30,647 Total operating expenses 36,695 37,458 145,599 130,713 Loss from operations Interest and other income , net 2,312 87 3,652 390 Net loss Net loss attributable to common stockholders $ $ $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 72,368,539 38,479,221 54,673,572 38,316,273 _______________________ Includes the following stock-based compensation expense: Research..."
01/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Company Presentation, dated January 2023",
"Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises"
01/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio"
11/03/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
07/08/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy"
03/01/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023"
02/22/2022 8-K Quarterly results
02/03/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/20/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors BRISBANE, Calif., January 20, 2022 - Annexon, Inc . , a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced the appointment of biotech executive Bettina M. Cockroft, M.D., senior vice president and chief medical officer of Sangamo Therapeutics, Inc., to the company's board of directors. “We are very pleased to welcome Bettina to the Annexon board of directors, as she brings extensive experience leading clinical organizations with a focus on neurodegenerative and movement disorders,” said Douglas Love, Esq., president and chief executive officer of Annexon...."
01/10/2022 8-K Investor presentation
Docs: "Company Presentation"
01/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington's Disease Following Six-Month Treatment"
11/09/2021 8-K Quarterly results
Docs: "Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results $271 Million Cash and Investments at End of Third Quarter 2021 Supports Operating Runway into 2024, Including Several Key Clinical Milestones across the Portfolio"
10/04/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results, Appointed a new director
Docs: "Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update – Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –"
07/22/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases"
06/08/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
02/08/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/22/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 18, 2020 ANNEXON, INC. Delaware 001-39402 27-5414423 180 Kimball Way, Suite 200 South San Francisco, California 94080 Registrant's telephone number, including area code: 822-5500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) &#9...",
"Lease, by and between Annexon, Inc. and HCP LS Brisbane, LLC"
11/16/2020 8-K Quarterly results
Docs: "Initiated Phase 2 trial evaluating ANX005 in Huntington’s Disease . Initiated patient dosing in a Phase 2 trial designed to assess safety, tolerability, and biomarkers of target engagement and impact on neurodegeneration • Initiated Phase 1 first-in-human trial of ANX009. Initiated subcutaneous dosing of healthy volunteers with Annexon’s third clinical-stage drug candidate in a Phase 1 trial designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses • Completed enrollment of Guillain-Barré Syndrome Drug-Drug Interaction trial. Fully enrolled global Phase 1b DDI trial assessing safety and potential pharmacokinetic effect of ANX005 co-administered with IVIg in GBS patients. Data are anticipated in early 2021 Anticipated..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy